Literature DB >> 2649128

Monoclonal antibodies for imaging and therapy.

A A Epenetos1, C Kosmas.   

Abstract

Mesh：

Substances：

Year:  1989        PMID： 2649128      PMCID： PMC2246996          DOI： 10.1038/bjc.1989.32

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  33 in total

1.  Reshaping human antibodies: grafting an antilysozyme activity.

Authors:  M Verhoeyen; C Milstein; G Winter
Journal:  Science       Date:  1988-03-25       Impact factor: 47.728

2.  Hybrid hybridomas and their use in immunohistochemistry.

Authors:  C Milstein; A C Cuello
Journal:  Nature       Date:  1983 Oct 6-12       Impact factor: 49.962

3.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

4.  Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture.

Authors:  J Taylor-Papadimitriou; J A Peterson; J Arklie; J Burchell; R L Ceriani; W F Bodmer
Journal:  Int J Cancer       Date:  1981-07-15       Impact factor: 7.396

5.  Evidence for a novel hybrid immunotoxin recognizing ricin A-chain by one antigen-combining site and a prostate-restricted antigen by the remaining antigen-combining site: potential for immunotherapy.

Authors:  K S Webb; J L Ware; S F Parks; P J Walther; D F Paulson
Journal:  Cancer Treat Rep       Date:  1985-06

6.  Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody.

Authors:  P A Farrands; A C Perkins; M V Pimm; M J Embleton; J D Hardy; R W Baldwin; J D Hardcastle
Journal:  Lancet       Date:  1982-08-21       Impact factor: 79.321

7.  Generation of human monoclonal antibodies reactive with cellular antigens.

Authors:  R J Cote; D M Morrissey; A N Houghton; E J Beattie; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

8.  Human hybridomas from malignant gliomas.

Authors:  K Sikora; T Alderson; J Phillips; J V Watson
Journal:  Lancet       Date:  1982-01-02       Impact factor: 79.321

9.  Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy.

Authors:  R W Schroff; K A Foon; S M Beatty; R K Oldham; A C Morgan
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

10.  Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein.

Authors:  P Horan Hand; D Colcher; D Salomon; J Ridge; P Noguchi; J Schlom
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701
View more
  10 in total

Review 1.  Applications of monoclonal antibodies in the investigation, diagnosis, and treatment of retinoblastoma.

Authors:  J F Tarlton; D L Easty
Journal:  Br J Ophthalmol       Date:  1993-12       Impact factor: 4.638

2.  Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer.

Authors:  G E Goodman; I Hellstrom; D E Yelton; J L Murray; S O'Hara; E Meaker; L Zeigler; P Palazollo; C Nicaise; J Usakewicz
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

3.  Radioiodinated anti-hepatocellular carcinoma (HCC) ferritin. Targeting therapy, tumor imaging and anti-antibody response in HCC patients with hepatic arterial infusion.

Authors:  Z Fan; Z Tang; K Liu; D Zhou; J Lu; A Yuan; H Zhao
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

4.  Anti-CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer.

Authors:  G Buccheri; A Biggi; D Ferrigno; M Quaranta; A Leone; G Vassallo; F Pugno
Journal:  Thorax       Date:  1996-04       Impact factor: 9.139

5.  Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.

Authors:  P Ragnhammar; J Fagerberg; J E Frödin; P Wersäll; L O Hansson; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

6.  Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy.

Authors:  K Bosslet; A Steinstraesser; P Hermentin; L Kuhlmann; A Bruynck; M Magerstaedt; G Seemann; A Schwarz; H H Sedlacek
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

Review 7.  Systemic immunotoxin therapy of cancer: advances and prospects.

Authors:  E J Wawrzynczak
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

8.  In vivo measurement of the association constant of a radio-labelled monoclonal antibody in experimental immunotargeting.

Authors:  J G Fjeld; H B Benestad; T Stigbrand; K Nustad
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

Review 9.  The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis.

Authors:  R Chowdhury; B Ganeshan; S Irshad; K Lawler; M Eisenblätter; H Milewicz; M Rodriguez-Justo; K Miles; P Ellis; A Groves; S Punwani; T Ng
Journal:  Br J Radiol       Date:  2014-03-06       Impact factor: 3.039

10.  Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.

Authors:  M Gerretsen; A H Schrijvers; M van Walsum; B J Braakhuis; J J Quak; C J Meijer; G B Snow; G A van Dongen
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.